Cargando…

A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process

OBJECTIVES: As part of the National Institute for Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process, manufacturers present submissions outlining the clinical and cost-effectiveness of new technologies. These submissions are critically appraised by Evidence Review Groups...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaltenthaler, Eva C, Dickson, Rumona, Boland, Angela, Carroll, Christopher, Fitzgerald, Patrick, Papaioannou, Diana, Akehurst, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Group 2012
Materias:	Health Policy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277905/ https://www.ncbi.nlm.nih.gov/pubmed/22318664 http://dx.doi.org/10.1136/bmjopen-2011-000562

Ejemplares similares

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties
por: Dickson, Rumona, et al.
Publicado: (2018)

Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020
por: Polak, Tobias B, et al.
Publicado: (2022)

The NICE Medical Technologies Evaluation Programme (MTEP): manufacturer submission challenges
por: Sprange, Kirsty, et al.
Publicado: (2012)

Audit of data redaction practices in NICE technology appraisals from 1999 to 2019
por: Osipenko, Leeza
Publicado: (2021)

Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals
por: Polak, Tobias B, et al.
Publicado: (2022)

Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process
por: Kaltenthaler, Eva, et al.
Publicado: (2016)

NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium
por: Ford, John A, et al.
Publicado: (2012)

The impact of rarity in NICE’s health technology appraisals
por: Clarke, Sophie, et al.
Publicado: (2021)

The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review
por: Meregaglia, Michela, et al.
Publicado: (2022)

Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
por: Hashem, Ferhana, et al.
Publicado: (2017)

Nature and reporting characteristics of UK health technology assessment systematic reviews
por: Carroll, Christopher, et al.
Publicado: (2018)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process
por: Walton, M. J., et al.
Publicado: (2019)

Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Fleeman, Nigel, et al.
Publicado: (2019)

The NICE Evidence Standards Framework for digital health and care technologies – Developing and maintaining an innovative evidence framework with global impact
por: Unsworth, Harriet, et al.
Publicado: (2021)

NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias
por: Brown, Patrick, et al.
Publicado: (2011)

Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma: A NICE Single Technology Appraisal
por: Greenhalgh, Janette, et al.
Publicado: (2013)

Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Bresnahan, Rebecca, et al.
Publicado: (2023)

UK must invest in quantum technology
por: Cartlidge, E
Publicado: (2001)

Impact of the National Institute for Health and Care Excellence (NICE) guidance on medical technology uptake: analysis of the uptake of spinal cord stimulation in England 2008–2012
por: Vyawahare, Bharati, et al.
Publicado: (2014)

Why the UK should invest in accelerator technology
por: Peach, Kenneth J
Publicado: (2000)

A change in the NICE guidelines on antibiotic prophylaxis: British Heart Valve Society update
por: Chambers, John B, et al.
Publicado: (2017)

Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
por: Latimer, Nicholas R., et al.
Publicado: (2014)

It’s not evidence, it’s insight: bringing patients’ perspectives into health technology appraisal at NICE
por: Staley, Kristina, et al.
Publicado: (2016)

Industry Use of Evidence to Influence Alcohol Policy: A Case Study of Submissions to the 2008 Scottish Government Consultation
por: McCambridge, Jim, et al.
Publicado: (2013)

Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study
por: Lexchin, Joel
Publicado: (2019)

Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis
por: Hale, George, et al.
Publicado: (2023)

Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Stainthorpe, Angela, et al.
Publicado: (2018)

Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Lambe, Tosin, et al.
Publicado: (2018)

Exploring reasons behind UK doctors leaving the medical profession: a series of qualitative interviews with former UK doctors
por: Pathmanathan, Arin, et al.
Publicado: (2023)

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Wijnen, Ben, et al.
Publicado: (2022)

Evaluation of US oncology electronic health record real-world data to reduce uncertainty in health technology appraisals: a retrospective cohort study
por: Mpofu, Philani, et al.
Publicado: (2023)

Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Fleeman, Nigel, et al.
Publicado: (2019)

Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Stainthorpe, Angela, et al.
Publicado: (2020)

Using HTA and guideline development as a tool for research priority setting the NICE way: reducing research waste by identifying the right research to fund.
por: Sharma, Tarang, et al.
Publicado: (2018)

Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Mistry, Hema, et al.
Publicado: (2017)

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

A Review of Economic Models Submitted to NICE’s Technology Appraisal Programme, for Treatments of T1DM & T2DM
por: Daly, Marie-Josée, et al.
Publicado: (2022)

Doctors' experiences and their perception of the most stressful aspects of complaints processes in the UK: an analysis of qualitative survey data
por: Bourne, Tom, et al.
Publicado: (2016)

Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Houten, Rachel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rqomf7cd3freeeusuopbf8ref1